Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo and Yervoy Plus Chemotherapy in Advanced Gastric Cancer
NCT05144854Phase 3Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in gastric cancer (GC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Overall survival at 3 years. Started Nov 2021; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05144854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144854.